Approval · Notice of Compliance 29625 · 2022
ALDACTONE: Notice of Compliance 29625
Issued December 2, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 29625
- Date
- December 2, 2022
- Company
- Pfizer Canada UlcKirkland, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Updates to the Product Monograph Product Monograph Reformatted to the Master Template
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ALDACTONE | Not yet assigned | — |
Medicinal ingredients
- SPIRONOLACTONE 25 MG per TAB
- SPIRONOLACTONE 100 MG per TAB